Article Text

  1. A S Al-Makadma1,
  2. S I Al-Akash2
  1. 1King Fahad Medical City-Children’s Hospital, Riyadh, Saudi Arabia
  2. 2Driscoll Children’s Hospital, Corpus Christi, TX, USA


Background and objectives Mycophenolate mofetil (MMF) has emerged as a new agent for treatment of a variety of glomerular diseases. This study examines the safety and efficacy of MMF in treating pediatric patients with steroid-dependent (SD) and/or frequently relapsing (FR) nephrotic syndrome (NS).

Methods We retrospectively reviewed the medical records of 18 patients with SDNS and/or FRNS treated with MMF for at least 3 months. MMF was used in 11 patients with SDNS (n = 10) and FRNS (n = 1), including 7 males and 4 females.

Results Mean age at time of diagnosis of NS was 3.3 years (range 1.1–8.5 years), and at the start of MMF 5.9 years (range 2.9–10 years). Seven patients had a renal biopsy prior to starting MMF; all had mesangial proliferative glomerulonephritis. Mean follow-up after starting MMF was 12.2 months (range 4–24 months). Mean MMF dose was 948 mg/m2/day (range 500–1087 mg/m2/day). MMF resulted in improvement in 9 of 11 patients, with 8 patients weaned off steroids completely, with a reduction in the mean relapse rate from 4.7 relapses/patient/year (range 2.4–6) before MMF to 1.05 relapses/patient/year (range 0–4.5) after MMF therapy (p = 0.0001). The relative risk for relapse before MMF was 4.7 (p = 0.0002). None of the patients had significant adverse events or intolerance to MMF therapy.

Conclusion We conclude that MMF is a safe and effective option for treatment of children with SDNS and/or FRNS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.